Xtherapeutics ApS: Financial statements 2025
CVR: 37384089
Source: annual report 2025, Danish Business Authority
01/07/2024 – 30/06/2025
Xtherapeutics ApS (CVR 37384089) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK -14,323 the year before. Equity in the 2025 report amounted to DKK -18,439.
- Gross Profit
- DKK 0
- Profit/Loss
- DKK 0
- Equity
- DKK -18,439
- Total Assets
- DKK 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 0 | 0 | -18 t. | - |
| 2024 | - | -14 t. | -14 t. | -18 t. | - |
| 2023 | - | -17 t. | -17 t. | -4 t. | - |
| 2022 | - | -9 t. | -14 t. | 13 t. | - |
| 2021 | - | - | -5 t. | -13 t. | - |
Official annual report
How creditworthy is Xtherapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Xtherapeutics ApS has published its annual report for 2024. Gross profit came to DKK -14,323, and the net result was DKK -14,323.
About Xtherapeutics ApS
Xtherapeutics ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Xtherapeutics IVS and Vaccex IVS. The management consists of Thomas Lars Andresen. The company is owned by Jonas Rosager Henriksen, Anders Elias Hansen and TLA-HOLDING 2010 ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK -14,323 the year before. Equity in the 2025 report amounted to DKK -18,439.